Evidence map›Paper›PMID 41436137›Full record

ArticleRMD open2025

Treatment with caspase-1 inhibitor diminishes kidney disease in MRL-

Paul Claßen, Myriam Meineck, Matthias Plath, Sabrina Saurin, Federica Fasola, Andrea Pautz, Andreas Schwarting, Simone Cosima Boedecker-Lips, Julia Weinmann-Menke

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in RMD open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Paul ClaßenDepartment of Internal Medicine I, University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany.ORCID 0000-0002-9410-0525
Myriam MeineckDepartment of Internal Medicine I, University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany.
Matthias PlathDepartment of Internal Medicine I, University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany.
Sabrina SaurinDepartment of Internal Medicine I, University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany.
Federica FasolaDepartment of Internal Medicine I, University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany.
Andrea PautzInstitute of Pharmacology, University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany.
Andreas SchwartingDepartment of Internal Medicine I, University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany.
Simone Cosima Boedecker-LipsDepartment of Internal Medicine I, University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany.
Julia Weinmann-MenkeDepartment of Internal Medicine I, University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany Julia.Weinmann-Menke@unimedizin-mainz.de.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesTo investigate the therapeutic potential of caspase-1 inhibition in systemic lupus erythematosus (SLE) and lupus nephritis (LN) using the MRL-

methodsFemale Murphy Roths large (MRL)-

resultsCaspase-1 inhibition significantly reduced systemic inflammation, lymphadenopathy and skin lesions in MRL-

conclusionsCaspase-1 inhibition effectively ameliorates both systemic and renal manifestations of SLE in MRL-

Indexed as

Caspase 1Caspase InhibitorsLupus Erythematosus, SystemicLupus NephritisAnimalsCytokinesDisease Models, AnimalDisease ProgressionFemaleKidneyMiceMice, Inbred MRL lprProteinuriaCaspase 1Caspase InhibitorsCytokinesAutoimmune DiseasesInflammationLupus NephritisSystemic Lupus Erythematosus

Identifiers

PMID41436137
PMCPMC12730834

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.